22 June 2016 - NICE has today published final guidance which recommends UK pharma major GlaxoSmithKline’s Benlysta (belimumab) for treating systemic lupus erythematosus.

Belimumab is recommended as an option as add-on treatment for active autoantibody-positive systemic lupus erythematosus in adults only if all of the following apply:

• There is evidence for serological disease activity (defined as positive anti-double-stranded DNA and low complement) and a Safety of Estrogen in Lupus National Assessment – Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score of greater than or equal to 10 despite standard treatment.
• Treatment with belimumab is continued beyond 24 weeks only if the SELENA-SLEDAI score has improved by 4 points or more.
• The company provides belimumab with the discount agreed in the patient access scheme.

For more details, go to: http://www.thepharmaletter.com/article/nice-gives-conditional-backing-for-gsk-s-benlysta-in-lupus

View entry in MAESTrO